Search Results - "WIRSHING, W. C"

Refine Results
  1. 1

    Novel antipsychotics : Comparison of weight gain liabilities by WIRSHING, D. A, WIRSHING, W. C, KYSAR, L, BERISFORD, M. A, GOLDSTEIN, D, PASHDAG, J, MINTZ, J, MARDER, S. R

    Published in The journal of clinical psychiatry (01-06-1999)
    “…We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative weight gain liabilities…”
    Get full text
    Journal Article
  2. 2

    Novel antipsychotics and new onset diabetes by Wirshing, Donna A., Spellberg, Brad J., Erhart, Stephen M., Marder, Stephen R., Wirshing, William C.

    Published in Biological psychiatry (1969) (15-10-1998)
    “…Background: The new antipsychotics induce minimal extrapyramidal side effects, probably due to their relatively greater affinity for certain nondopaminergic…”
    Get full text
    Journal Article
  3. 3

    Movement disorders associated with neuroleptic treatment by Wirshing, W C

    “…Neuroleptic-induced movement disorders, or extrapyramidal side effects (EPS), can be classified into acute and tardive syndromes. Among the former are…”
    Get full text
    Journal Article
  4. 4

    Informed Consent: Assessment of Comprehension by Wirshing, Donna A., Wirshing, William C., Marder, Stephen R., Liberman, Robert P., Mintz, Jim

    Published in The American journal of psychiatry (01-11-1998)
    “…Objective:The authors designed and evaluated a structured and rigorous informed consent procedure involving subjects with schizophrenia.Method:Informed consent…”
    Get full text
    Journal Article
  5. 5

    Risperidone in Treatment-Refractory Schizophrenia by Wirshing, Donna A., Marshall, Jr, Barringer D., Green, Michael F., Mintz, Jim, Marder, Stephen R., Wirshing, William C.

    Published in The American journal of psychiatry (01-09-1999)
    “…OBJECTIVE: The purpose of this study was to evaluate the clinical safety and efficacy of risperidone compared to haloperidol in patients with…”
    Get full text
    Journal Article
  6. 6

    Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection by Aravagiri, M, Marder, S R, Wirshing, D, Wirshing, W C

    Published in Pharmacopsychiatry (01-05-1998)
    “…A simple, sensitive and accurate method for the simultaneous determination of risperidone (RSP) and its 9-hydroxy metabolite (9-OH-RSP) in human plasma is…”
    Get more information
    Journal Article
  7. 7

    Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia by Marder, S R, Wirshing, W C, Mintz, J, McKenzie, J, Johnston, K, Eckman, T A, Lebell, M, Zimmerman, K, Liberman, R P

    Published in The American journal of psychiatry (01-12-1996)
    “…The authors evaluated the effectiveness of behaviorally oriented social skills training and supportive group therapy for improving the social adjustment of…”
    Get more information
    Journal Article
  8. 8

    Does risperidone improve verbal working memory in treatment-resistant schizophrenia? by GREEN, M. F, MARSHALL, B. D, WIRSHING, W. C, AMES, D, MARDER, S. R, MCGURK, S, KERN, R. S, MINTZ, J

    Published in The American journal of psychiatry (01-06-1997)
    “…OBJECTIVE: Treatment efficacy in schizophrenia is typically defined in terms of symptom reduction. However, new antipsychotic medications could potentially…”
    Get full text
    Journal Article
  9. 9

    Risperidone versus Haloperidol on Secondary Memory: Can Newer Medications Aid Learning? by Kern, Robert S., Green, Michael F., Marshall, Barringer D., Wirshing, William C., Wirshing, Donna, McGurk, Susan R., Marder, Stephen R., Mintz, Jim

    Published in Schizophrenia bulletin (01-01-1999)
    “…The introduction of the new generation of antipsychotic medications for the treatment of schizophrenia has been accompanied by a growing interest in the…”
    Get full text
    Journal Article
  10. 10

    Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate by Marder, S.R., Aravagiri, M., Wirshing, W.C., Wirshing, D.A., Lebell, M., Mintz, J.

    Published in Schizophrenia research (2002)
    “…Background: Finding a dose of an antipsychotic for maintenance therapy that is both safe and effective can be difficult because clinicians are unable to…”
    Get full text
    Journal Article
  11. 11

    Plasma level monitoring of olanzapine in patients with schizophrenia : Determination by high-performance liquid chromatography with electrochemical detection by ARAVAGIRI, M, AMES, D, WIRSHING, W. C, MARDER, S. R

    Published in Therapeutic drug monitoring (01-06-1997)
    “…A sensitive high-performance liquid chromatography method with electrochemical detection for the determination of olanzapine in human plasma is described…”
    Get full text
    Journal Article
  12. 12

    Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients by Kern, Robert S, Green, Michael F, Marshall, Barringer D, Wirshing, William C, Wirshing, Donna, McGurk, Susan, Marder, Stephen R, Mintz, Jim

    Published in Biological psychiatry (1969) (15-10-1998)
    “…Background: The present study compared the effects of risperidone vs. haloperidol on reaction time, manual dexterity, and two types of motor learning in a…”
    Get full text
    Journal Article
  13. 13

    Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia by De Deyn, P P, Wirshing, W C

    “…Advances in the assessment of the behavioral and psychological symptoms of dementia (BPSD) have been employed in large-scale clinical trials of new…”
    Get full text
    Journal Article
  14. 14

    Neuroleptic Plasma Levels by Van Putten, Theodore, Marder, Stephen R, Wirshing, William C, Aravagiri, Manickam, Chabert, Nicole

    Published in Schizophrenia bulletin (1991)
    “…There is enormous variation in plasma levels of most neuroleptics in patients on the same dose. Much of the past research on the relation between plasma levels…”
    Get full text
    Journal Article
  15. 15

    Technique for training schizophrenic patients in illness self-management: a controlled trial by Eckman, T A, Wirshing, W C, Marder, S R, Liberman, R P, Johnston-Cronk, K, Zimmermann, K, Mintz, J

    Published in The American journal of psychiatry (01-11-1992)
    “…To determine whether schizophrenic outpatients receiving low-dose neuroleptic therapy could learn and retain complex information and skills related to…”
    Get more information
    Journal Article
  16. 16

    Repetitive and compulsive behavior in frontal lobe degenerations by Ames, D, Cummings, J L, Wirshing, W C, Quinn, B, Mahler, M

    “…The authors review the relationship of repetitive behaviors to frontal lobe degenerations and report the repetitive and compulsive behaviors, radiologic…”
    Get more information
    Journal Article
  17. 17

    The effects of novel antipsychotics on glucose and lipid levels by WIRSHING, Donna A, BOYD, Jennifer A, MENG, Laura R, BALLON, Jacob S, MARDER, Stephen R, WIRSHING, William C

    Published in The journal of clinical psychiatry (01-10-2002)
    “…The novel antipsychotics are extensively used based on their favorable extrapyramidal side effect profiles. However, accumulating evidence suggests that these…”
    Get full text
    Journal Article
  18. 18

    Bromocriptine reduces cigarette smoking by Jarvik, Murray E., Caskey, Nicholas H., Wirshing, William C., Madsen, Damian C., Iwamoto-Schaap, Paula N., Elins, Julie L.

    Published in Addiction (Abingdon, England) (01-08-2000)
    “…Aims. Animal studies have shown that nicotine releases dopamine, a neurotransmitter implicated in drug reinforcement. We hypothesized that bromocriptine would…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Predictive value of eosinophilia for neutropenia during clozapine treatment by AMES, D, WIRSHING, W. C, BAKER, R. W, UMBRICHT, D. S. G, SUN, A. B, CARTER, J, SCHOOLER, N. R, KANE, J. M, MARDER, S. R

    Published in The journal of clinical psychiatry (01-12-1996)
    “…Myelotoxicity continues to hinder the widespread use of clozapine in the United States. It has been theorized that eosinophilia predicts later agranulocytosis…”
    Get full text
    Journal Article